15 Korean listed companies ended 2025 with negative equity, and together they are 0.03% of market value
Of 2,577 companies with a reported equity figure, 15 (0.6%) had total equity of zero or below: 8 on KOSDAQ, 3 on KOSPI and 4 of 13 measured on KONEX. Fourteen reported a net loss. The largest was worth 526 billion won.
AI-assisted, human-reviewed sourcing. Figures are pulled programmatically from the official sources listed at the end of this article and checked by an editor before publication.
korea negative equitykorean listed companies liabilities exceed assetskospi kosdaq konex negative shareholders equitykorea balance sheet deficitdart annual reports
Total equity is what is left on the balance sheet when all liabilities are subtracted from all assets. When it is zero or below, the company owes more than it owns on paper. We read total equity from each company’s fiscal-2025 annual report and counted the cases at or below zero.
The count
15 of 2,577 companies with an equity figure ended 2025 at zero or below: 0.6%. None was exactly at zero.
| Market | Companies with equity figure | Equity at or below zero | Share |
|---|---|---|---|
| KOSDAQ | 1,746 | 8 | 0.5% |
| KOSPI | 818 | 3 | 0.4% |
| KONEX | 13 | 4 | not computed (13 measured) |
| All | 2,577 | 15 | 0.6% |
KONEX has only 13 companies with a figure, so we show the count and leave the share out.
The six largest by market value
| Company | Market cap (12 Nov 2026) | Total equity | Net income 2025 |
|---|---|---|---|
| STX Corporation | 526.3 billion won | -49.4 billion | -166.4 billion |
| Sambu Construction | 227.8 billion | -142.1 billion | -76.7 billion |
| Union Korea Pharm | 192.4 billion | -22.9 billion | -30.8 billion |
| Eone Diagnomics Genome Center | 167.1 billion | -22.5 billion | +28.2 billion |
| Dawonsys | 96.6 billion | -515.6 billion | -196.9 billion |
| EOFlow | 75.2 billion | -144.0 billion | -42.4 billion |
Twelve of the 15 have a market value in the price file. Together they were worth 1.40 trillion won, which is 0.03% of the 4,643.1 trillion won in the whole market. The largest of them, STX Corporation, was worth less than one-two-thousandth of Samsung Electronics.
Loss and deficit
Fourteen of the 15 reported a net loss for 2025. One, Eone Diagnomics Genome Center, reported a net profit of 28.2 billion won and still had negative equity. A profit in one year and a deficit on the balance sheet can sit together when earlier losses were larger.
Where they are
The 15 are spread across 11 industry names. General Construction has two of its 38 measured companies in the group, Research and Development two of 65, Medicinal Substances and Pharmaceuticals two of 180, and Medical, Precision, and Optical Instruments two of 100. The rest have one each. Because every count is two or less, we do not rank industries here.
Thirteen of the 15 are measured on a consolidated basis and two on a separate basis.
What this does not say
A balance sheet at one date does not tell what happens next. We do not know whether any of the 15 raised capital, converted debt or sold assets after year-end, because the tape holds only the annual report. We also did not apply the legal impairment test, which compares equity with registered capital and would give a different, larger list.
This is statistics, not you or your company.
Related: 888 companies owe more than their equity and accumulated deficits at 24% of companies.
Data & Verification Notes
- Data as of
- Sources
- Financial Supervisory Service (Korea, Open DART) — Annual financial statements (report code 11011), fiscal year 2025: total equity, total assets, net income, consolidated where available
- SeoulMarkets — Korea Valuation Tape, market capitalisation priced 12 November 2026
- Cross-checks
- Companies with a total equity figure: 2,577 of 2,709 (KOSDAQ 1,746, KOSPI 818, KONEX 13). Equity of zero or below: 15 (0.6%); exactly zero: none.
- By market: KOSDAQ 8 of 1,746, KOSPI 3 of 818, KONEX 4 of 13.
- Net income of the 15: net loss 14, net profit 1 (Eone Diagnomics Genome Center, 28.2 billion won).
- Market capitalisation available for 12 of the 15; together 1.40 trillion won, which is 0.03% of 4,643.1 trillion won (the 2,683 rows with a market capitalisation).
- Reporting basis: consolidated 13, separate 2.
- Largest by market value: STX Corporation 526.3 billion won (equity -49.4 billion), Sambu Construction 227.8 billion (-142.1), Union Korea Pharm 192.4 billion (-22.9), Eone Diagnomics Genome Center 167.1 billion (-22.5), Dawonsys 96.6 billion (-515.6), EOFlow 75.2 billion (-144.0).
- Excluded figures
- 132 of 2,709 companies are not counted: no equity figure in the fiscal-2025 annual report data.
- Korean company law has its own test for capital impairment, which compares equity with registered capital. We did not apply it; this article counts only equity at or below zero.
- A negative equity figure at the end of 2025 does not show the company's position today. We have the year-end balance sheet only, not later filings, rescue plans or share issues.
- Three of the 15 have no market capitalisation in the price file, so their value is not counted.
- This is not investment advice.
The full dataset behind these figures — every listed company, every row — is available to license. SeoulMarkets data for licence →
Not investment advice. SMarkets publishes data journalism for general information only. Nothing here is investment advice, a recommendation, or an offer to buy or sell any security — any investment you make is at your own risk and responsibility. Figures are derived from official public data sources and may be revised by the issuing agency. Verify independently before acting.
← More Equities